Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice -: Possible role of leptin in stimulation of HDL turnover

被引:108
|
作者
Silver, DL [1 ]
Jiang, XC [1 ]
Tall, AR [1 ]
机构
[1] Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA
关键词
D O I
10.1074/jbc.274.7.4140
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Abnormalities of plasma high density lipoprotein (HDL) levels commonly reflect altered metabolism of the major HDL apolipoproteins, apoA-I and apoA-II, but the regulation of apolipoprotein metabolism is poorly understood. Two mouse models of obesity, ob/ob and db/db, have markedly increased plasma HDL cholesterol levels. The purpose of this study was to evaluate mechanisms responsible for increased HDL in ob/ob mice and to assess potential reversibility by leptin administration. ob/ob mice were found to have increased HDL cholesterol (2-fold), apoA-I (1.3-fold), and apoA-II (4-fold). ApoA-I mRNA was markedly decreased (to 25% of wildtype) and apoA-II mRNA was unchanged, suggesting a defect in HDL catabolism, HDL apoprotein turnover studies using nondegradable radiolabels confirmed a decrease in catabolism of apoA-I and apoA-II and a 4-fold decrease in hepatic uptake in ob/ob mice compared with wild-type, but similar renal uptake, Low dose leptin treatment markedly lowered HDL cholesterol and apoA-II levels in both ob/ob mice and in lean wild-type mice, and it restored apoA-I mRNA to normal levels in ob/ob mice. These changes occurred without significant alteration in body weight, Moreover, ob/ob neuropeptide Y-/- mice, despite marked attenuation of diabetes and obesity phenotypes, showed no change in HDL cholesterol levels relative to ob/ob mice. Thus, increased HDL levels in ob/ob mice reflect a marked hepatic catabolic defect for apoA-I and apoA-II, In the case of apoA-I, this is offset by decreased apoA-I mRNA, resulting in apoA-II-rich HDL particles. The studies reveal a specific HDL particle catabolic pathway that is downregulated in ob/ob mice and suggest that HDL apolipoprotein turnover may be regulated by obesity and/or leptin signaling.
引用
收藏
页码:4140 / 4146
页数:7
相关论文
共 40 条
  • [21] DIFFERENT EFFECTS OF SUBCLASSES OF HDL, CONTAINING APOA-I BUT NOT APOA-II (LPA-I) ON CHOLESTEROL ESTERIFICATION IN PLASMA AND NET CHOLESTEROL EFFLUX FROM FOAM CELLS
    OHTA, T
    SAKU, K
    TAKATA, K
    NAKAMURA, R
    IKEDA, Y
    MATSUDA, I
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) : 956 - 962
  • [22] Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor
    Masson, David
    Koseki, Masahiro
    Ishibashi, Minako
    Larson, Christopher J.
    Miller, Stephen G.
    King, Bernard D.
    Tall, Alan R.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (12) : 2054 - U170
  • [23] Human secretory phospholipase A2 (sPLA2) mediates decreased plasma levels of HDL-cholesterol and ApoA-I in response to inflammation in human ApoA-I transgenic mice
    Tietge, UJ
    Maugeais, C
    Lund-Katz, S
    Grass, D
    De Beer, FC
    Rader, DJ
    CIRCULATION, 2001, 104 (17) : 269 - 269
  • [24] Transgenic rabbits expressing both human ApoA-I and LCAT have a protective lipoprotein profile with increased HDL and enhanced LDL catabolism
    Shamburek, RD
    Hoeg, JM
    Duverger, N
    Houbebine, LM
    Hoyt, RF
    Wood, DO
    Santamarina-Fojo, S
    Brewer, HB
    CIRCULATION, 1999, 100 (18) : 402 - 402
  • [25] EFFECT OF LYSOLECITHIN ON THE BINDING OF 1-ANILINO-8-NAPHTHALENE SULFONATE TO APOHDL, APOA-I OR APOA-II FROM HUMAN-SERUM HIGH-DENSITY LIPOPROTEIN
    YOSHINO, H
    MINARI, O
    JOURNAL OF BIOCHEMISTRY, 1980, 87 (05): : 1357 - 1363
  • [26] Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I - Effect of lipid association and APOA-I mutations on receptor binding
    Liadaki, KN
    Liu, T
    Xu, SZ
    Ishida, BY
    Duchateaux, PN
    Krieger, JP
    Kane, J
    Krieger, M
    Zannis, VI
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) : 21262 - 21271
  • [27] Treatment with a potent & selective PPAR-α agonist LY518674 significantly increases ApoA-I and ApoA-II production rates in patients with metabolic syndrome despite no change in HDL
    Millar, John S.
    Duffy, Danielle
    Gadi, Ramprasad
    Bloedon, LeAnne T.
    Dunbar, Richard L.
    Wolfe, Megan L.
    Movva, Rajesh
    Shah, Ashish
    Harris, Cynthia J.
    Wang, Ming-Dauh
    Howey, Daniel C.
    Rader, Daniel J.
    CIRCULATION, 2007, 116 (16) : 126 - 127
  • [28] ProteinChip technology: A new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease
    Dayal, B
    Ertel, NH
    JOURNAL OF PROTEOME RESEARCH, 2002, 1 (04) : 375 - 380
  • [29] Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL
    Cho, Kyung-Hyun
    MOLECULES, 2022, 27 (13):
  • [30] ApoA-I/SR-BI Double Knockout Mice Plasma Is Rich In Very Large HDL With High Free Cholesterol
    Tsujita, Maki
    Nakasuka, Kosuke
    Takase, Hiroshi
    Kamiya, Mayuko
    Mineo, Chieko
    Shaul, Philip W.
    Okuhira, Keiichiro
    Yokoyama, Shinji
    Remaley, Alan T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43